Previous Article | Next Article ![]()
Journal of Virology, August 2000, p. 7391-7399, Vol. 74, No. 16
Graduate Institute of
Microbiology1 and Department of
Otolaryngology, National Taiwan University
Hospital,2 College of Medicine, National
Taiwan University, Taipei, Taiwan, Republic of China
Received 27 January 2000/Accepted 22 May 2000
The Zta protein is a key transactivator involved in initiating the
Epstein-Barr virus (EBV) lytic cascade. In addition to transactivating
many viral genes, Zta has the capacity to influence host cellular
signals by binding to promoter regions or by interacting with several
important cellular factors. Based on the observation that tyrosine
kinases play central roles in determining the fate of cells, a kinase
display assay was used to investigate whether cells expressing Zta
have an altered pattern of kinase expression. The assay revealed
that TRK-related tyrosine kinase (TKT) is expressed at
significant levels in Zta transfectants but not in control cells.
Additional evidence was obtained from Northern and Western blotting.
Importantly, the upregulation of phosphorylated TKT and TKT
downstream effector matrix metalloproteinase 1 in Zta transfectants
hinted that TKT might initiate a signaling cascade in Zta-expressing
cells. In addition, deletion analysis of the Zta protein revealed that
the transactivation and dimerization domains were both essential for
the upregulation of TKT transcription. Moreover, correlation of
expression levels of Zta and TKT transcripts in nasopharyngeal
carcinoma biopsy specimens was clearly demonstrated by quantitative PCR
(Q-PCR), which provides the first evidence for an effect of Zta on
cellular gene expression in vivo. These findings offer insight into the
virus-cell interactions and may help us elucidate the role of EBV in tumorigenesis.
Through evolution, multicellular
organisms have developed an intricate cellular signaling network to
cope with changes in the cellular microenvironment. External stimuli
trigger signaling through various cellular molecules and so influence
the fate of the cell. Tyrosine kinases and the molecules upon which
they act constitute components of an important and tightly regulated
network of pathways. Under normal physiological conditions, these
tyrosine kinases are key cellular elements determining cell
proliferation, differentiation, and apoptosis (48). On the
other hand, tumor formation that escapes the regular control loop
usually involves a breakdown of restricted tyrosine kinase regulation,
leading to rapid or irregular growth or even metastasis
(26). Furthermore, it has been reported that the
transforming ability of several oncogenic viruses may be attributable
to activation or structural mimicking of tyrosine kinase receptors by
viral oncogenes. For example, v-sis of the simian sarcoma
retrovirus is a homolog of platelet-derived growth factor (PDGF) and
can activate PDGF receptor, and the E5 gene product of bovine
papillomavirus can activate PDGF receptor Epstein-Barr virus (EBV), a human herpesvirus, is capable of
immortalizing primate B cells and human primary epithelial cells in
vitro (25, 37). The oncogenic potential of EBV is
evident in vivo, since it causes B-cell lymphomas and promotes
metastasis in animal models (49, 50). Seroepidemiologic and
pathologic data reveal a strong association between EBV and
various malignancies, such as nasopharyngeal carcinoma
(NPC), B-cell proliferative disease in immunodeficient patients,
and lymphoepithelioma-like gastric carcinoma (33, 36, 58).
An unusual characteristic that differentiates EBV-associated tumors
from other human malignancies is that they rarely have mutations in
well-known tumor suppressor genes, such as the Rb and p53 genes, or in
well-defined proto-oncogenes (55, 56). Therefore, we
hypothesized that EBV may encode proteins that influence the normal
cellular signaling cascade, especially the versatile tyrosine kinase
family, in causing tumor formation.
A likely candidate, among EBV gene products, to influence the cellular
signaling cascade is the Zta protein. Structurally, Zta is a leucine
zipper DNA-binding protein; functionally, it acts as the key viral
transactivator and initiates the EBV lytic cascade (25), as
well as influencing many cellular genes (53). Based on data
from previous reports, there are three mechanisms through which Zta may
exert potent effects on cell signaling. First, Zta can activate several
promoters, such as c-Fos and transforming growth factor Cell culture.
The RHEK-1 cell line was established by
immortalizing primary human foreskin keratinocytes with adenovirus type
12-simian virus 40 (45). NPC-TW01 is an EBV-negative NPC
cell line (29). Both lines were maintained in Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum plus
100 U of penicillin per ml and 100 µg of streptomycin per ml. The
other NPC-derived cell line, HONE-1, was grown in RPMI 1640 medium with
the same supplements (15). Stable, Zta expression
transfectants or vector controls were cultured in the same medium as
that used for the parental cells, with 300 µg of neomycin (Gibco BRL,
Gaithersburg, Md.) per ml. For detection of MMP-1 transcripts, cells
were starved in Dulbecco's modified Eagle's medium without fetal
bovine serum 24 h prior to 3 days of 50 nM collagen I (Gibco BRL) treatment.
Plasmid construction.
pRc/CMV-Zta is a Zta expression
plasmid (B95-8 sequences; nucleotides 103742 to 101947) driven by the
cytomegalovirus promoter and was generously provided by M.-T. Liu
(National Taiwan University, Taipei, Taiwan).
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Upregulation of Tyrosine Kinase TKT by the
Epstein-Barr Virus Transactivator Zta
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(10, 22, 39,
40). Besides their direct effects in promoting cell growth, the
oncogenic mutated ras and v-src may induce the
activation of vascular endothelial growth factor, which is involved in
tumor angiogenesis, and this activation may play a role in enhancing
tumor formation (44).
(TGF-
),
or suppress c-Jun (5, 14, 47). The ability of Zta to
regulate AP1 protein expression and to compete with Fos-Jun
heterodimers for AP1 sites suggests that Zta has the potential to
interfere with AP1-mediated cell proliferation and differentiation
(53). Second, Zta may inhibit or cooperate with cellular
proteins by interacting with them, for example, NF-
B, p53, c-Myb,
and the retinoic acid receptor (11, 17, 24, 52, 66). Third,
Zta may modulate cellular transcription indirectly, through a
competitive interaction with the important cellular regulator
CREB-binding protein, since the interaction between Zta and
CREB-binding protein may influence the transcriptional efficiency of
other cellular proteins (1, 65). However, whether Zta
directly or indirectly influences any cellular tyrosine kinase remains
unknown. Utilizing a newly developed kinase display assay (27), we found that a cellular receptor tyrosine kinase, TKT (TRK-related tyrosine kinase, also called DDR2, Tyro 10, and CCK-2), could be upregulated by Zta at both the RNA and protein levels in a
cell culture system (2, 23, 28). Importantly, the upregulation of phosphorylated TKT and the TKT downstream effector matrix metalloproteinase 1 (MMP-1) hinted that TKT might initiate a
signaling cascade in Zta-expressing cells. Moreover, correlation of
expression levels of Zta and TKT transcripts in NPC biopsy specimens
was clearly demonstrated by quantitative PCR (Q-PCR), providing the
first evidence for an effect of Zta on cellular gene expression in
vivo. These findings offer insight into the virus-cell interactions and
may help us elucidate the role of EBV in tumorigenesis.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
), from
which the entire dimerization domain was deleted, was generated by
subcloning the EBV DNA fragment (B95-8 sequence from nucleotides 103250 to 101950) into the eukaryotic expression plasmid pRc/CMV (Invitrogen).
Transfection and establishment of Zta stable expression clones. Cells were transfected using a modified calcium phosphate method (7). Briefly, 20 µg of plasmid DNA in 360 µl of H2O was mixed with 40 µl of 2.5 M CaCl2 and 0.4 ml of 2× BBS [50 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (pH 6.95), 280 mM NaCl, 1.5 mM Na2HPO4] and incubated for 20 min at room temperature. The mixture was added dropwise to 50% confluent cells, which were then incubated for 20 h at 35°C under 3% CO2. After the medium was refreshed, transfectants were moved to a 37°C incubator containing 5% CO2. For the transient-transfection assay, cells were harvested 24 h after transfection. For selection of stable Zta-expressing clones, the transfectants were cultured in the presence of 400 µg (NPC-TW01 and HONE-1 cells) or 800 µg (RHEK-1) of neomycin per ml until sufficient cells were available for assay. To establish the inducible system, pUHD10.3-Zta and pUHD172-1neo were cotransfected into HONE-1 cells at a ratio of 10:1 and the clones were selected using neomycin (400 µg/ml).
Immunofluorescence assay.
Transfected cells were fixed to
the slides with acetone-methanol (1:1) at
20°C for 30 min. After
being incubated with anti-Zta antibody 4F10 or control antibody for
1 h at 37°C (59), the cell smears were washed and
incubated with 100-fold-diluted fluorescein isothiocyanate-conjugated
goat anti-mouse immunoglobulin G antiserum (Jackson, West Grove, Pa.).
After being washed with phosphate-buffered saline (PBS), the cells were
counterstained with Evans blue, mounted in 90% glycerol-PBS solution,
and examined under a UV fluorescence microscope.
Western blot analysis. Cells were lysed in KBO buffer (20 mM octyglucoside, 0.5% Triton X-100, 0.3 M NaCl, 0.025 M NaPO4 [pH 7.4], 10 µg of leupeptin per ml, 10 µg of aprotinin per ml, 1 mM phenylmethylsulfonyl fluoride) for analysis of Zta and TKT protein expression. A 20-µg portion of extracted protein was denatured at 100°C for 3 min and resolved on sodium dodecyl sulfate (SDS)-10% polyacrylamide gels. The proteins were electrotransferred onto a polyvinylidene difluoride nitrocellulose membrane (Millipore, Bedford, Mass.), and the blot was blocked and then incubated with anti-Zta antibody 4F10 (59), anti-TKT antibody (Santa Cruz, Santa Cruz, Calif.), anti-tubulin antibody (Amersham Pharmacia, Piscataway, N.J.), or anti-actin antibody (Sigma, St. Louis, Mo.) for 1 h. After being washed with Tris-buffered saline containing Tween 20 (TBS-T), the blot was incubated with peroxidase-labeled goat anti-mouse or rabbit anti-goat antibody (Jackson, Santa Cruz, Calif.). Finally, bands were visualized using the Renaissance kit (NEN, Boston, Mass.).
Kinase display. A tyrosine kinase display strategy was used to visualize the tyrosine kinase profile in Zta and vector transfectants (27). Total cellular RNA was extracted as specified by the manufacturer (REzol C&T; Protech, Taiwan, Republic of China). First, the cDNAs of tyrosine kinase were generated using 25 µg of total RNA as template and 2.4 µM degenerate primers in the reverse transcription (RT) reaction. The sequences of the degenerate primers for the RT reaction are as follows: TK-RTA, 5'-CCRHANGMCCA-3'; and TK-RTB, 5'-CCRHAVMTCCA-3'. The mixtures were then denatured at 65°C for 10 min, and 1 mM deoxynucleoside triphosphate (dNTP), 10 U of RNasin and 0.5 U of reverse transcriptase were added to give a 25-µl reaction mixture. RT was carried out at 42°C for 30 min. The mixtures were then purified by phenol-chloroform extraction and CHROMA SPIN-200 column chromatography (Clontech, Palo Alto, Calif.).
To trace the tyrosine kinase transcripts, the 5' primers were end labeled with [
-33P]ATP (25 µCi) at 37°C for 30 min
using polynucleotide kinase. Then the amplification was carried out in
1× buffer-0.8 mM MgCl2-0.2 mM dNTP-0.45 µM 3'-end
primer-0.25 µM 33P-labeled 5'-end primer-0.5 U of
Taq polymerase-5 µl of the above cDNA products in a
50-µl reaction volume. The sequences of the four 5'-end primers
(mixed 1:1:1:1) were as follows: 5TYKI-11, 5'CCAGGTCACCAARRTWDCRGAYTTYGG-3'; 5TYKI-12,
5'CCAGGTCACCAARRTWDCYGAYTTYGG-3'; 5TYKI-13,
5'CCAGGTCACCAARRTWWGYGAYTTYGG-3'; and 5TYKI-14,
5'CCAGGTCACCAARRTWGGNGAYTTYGG-3'. The sequences of three
3'-end primers (mixed 1:1:1) were as follows: TK-3A,
5'-CACAGGTTACCRHANGMCCARACRTC-3'; TK-3B,
5'-CACAGGTTACCRHARCTCCANACRTC-3'; and TK-3C,
5'-CACAGGTTACCRHANGMCCAYACRTC-3'. PCR amplification involved
5 cycles of 94°C for 45 s, 44°C for 90 s, and 72°C for 10 s followed by 25 cycles of 94°C for 45 s, 55°C for
90 s, and 72°C for 15 s. The 170-bp products were resolved
in a 3% Nusieve gel (FMC, Rockland, Maine), visualized by ethidium
bromide staining, and purified from the gel.
Eluted PCR products (8 × 104 cpm) were digested
separately with 16 restriction enzymes which target 4- to 5-bp sites:
AciI, AluI, AvaII, BsaHI,
Bsp1286I, HaeIII, HhaI,
HinfI, BsrI, BstNI, HpaII,
MnlI, MseI, MwoI, NciI, and
RsaI. The products were analyzed on a denaturing 7%
polyacrylamide gel containing 6 M urea and 0.6× TTE (glycerol
tolerance buffer [USB, Cleveland, Ohio]). The patterns of tyrosine
kinase expression may be determined from the pattern of restriction
enzyme digestion products (27).
PCR and Q-PCR. cDNA was synthesized using 5 µg of total RNA as the template and random hexamers as primers, as described in the manufacturer's protocol (Gibco BRL).
For qualitative PCR amplification, 25-µl reaction mixtures containing 2.5 µl of cDNA, 0.2 mM dNTP, 0.2 µM primers, 1× PCR buffer, and 1 U of Dynazyme II DNA polymerase (Finnzymes, Oy, Finland) were amplified for 25 or 40 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. The primers used in the PCR were as follows: TKT primers, 5'-GCGCCATGCAGGAGGTCATG-3' and 5'-CCACTCTCATACACACATTCA-3'; HP primers, 5'-TATGGACAGGACTGAACGTC-3' and 5'-GTTGAGAGATCATCTCCAACC-3'; Zta primers, 5'-TTCCACAGCCTGCACCAGTG-3' and 5'-GGCAGCAGCCACCTCACGGT-3'; and MMP-1 primers, 5'-CGGAATTCTGTGAGTCCAAAGAAGGTGT-3' and 5'-CGGAATTCAAGAGTTATCCCTTGCCTATC-3'. For Q-PCR, DNase I-treated RNA served as the template for the RT reaction. The reaction conditions were as specified by the manufacturer (Perkin-Elmer, Foster, Calif.), except that the Taq polymerase was replaced by Dynazyme. To detect Zta transcripts in the NPC biopsy specimens, the first-round PCR products were diluted 15-fold and then 1 µl was used as template for the second-round, nested PCR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was chosen as the internal control (TaqMan GAPDH control reagent; Perkin-Elmer). The relative amounts of indicated transcripts (40-Ct) were calculated as described previously (18). The nucleotide sequences of the probes and primers used in the Q-PCR are as follows: sequences for Zta, 5'-AGCAGCCACCTCACGGTAGTG-3' and 5'-AATCGGGTGGCTTCCAGAA-3' (primers) and 5'-CAGTTGCTTAAACTTGGCCCGGCA-3' (probe); sequences for TKT, 5'-AGTCAGTGGTCAGAGTCCACAGC-3' and 5'-CAGGGCACCAGGCTCCATC-3' (primers) and 5'-CCAAATATGGAAGGCTGGACTCAGAAG-3' (probe).Northern blot analysis. mRNA was purified from total cellular RNA using magnetic conjugated oligo(dT) beads (MACS, Auburn, Calif.). Denatured mRNA was separated on a 0.8% agarose gel and transferred onto membranes (Hybond-N; Amersham Pharmacia). To detect the TKT transcripts in Zta-expressing cells, a 32P-labeled RNA probe was prepared by in vitro transcription (TKT nucleotide sequences 425 to 1550 and 1616 to 2958). The blot was prehybridized for 2 h in prehybridization buffer (5× SSC [1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 0.2% SDS, 20 mM sodium phosphate buffer, 0.6% polyvinylpyrrolidone, 0.1% Ficoll, 50% foramide, 0.1% bovine serum albumin, 250 µg of denatured salmon sperm DNA per ml, 10 µg of tRNA per ml) and hybridized overnight in hybridization buffer (5× SSC, 10% sodium dextran sulfate, 0.2% SDS, 0.1% bovine serum albumin, 0.6% polyvinylpyrrolidone, 20 mM sodium phosphate buffer, 250 µg of denatured salmon sperm DNA per ml, 10 µg of tRNA per ml, 50% foramide) at 68°C. After stringent washing in 0.1% SDS-0.1× SSC for 5 h at 68°C with five or six changes of buffer, the signals were visualized using a PhosphorImager (Storm 840; Molecular Dynamics, Sunnyvale, Calif.).
Immunoprecipitation. Cells treated with 1 mM sodium vanadate for 90 min were solubilized with KBO lysis buffer as detailed above for the Western blot analysis. A 500-µg sample of protein was incubated overnight with 4 µg of antiphosphotyrosine antibody (4G10; Upstate Biotechnology, Lake Placid, N.Y.) or irrelevant mouse anti-actin antibody (Sigma) at 4°C. Then the immunocomplexes were precipitated with protein A-Sepharose at 4°C for 2 h and washed with PBS five times. Finally the immunoprecipitates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) (10% polyacrylamide) and the Western blot analysis was carried out as described above.
Biopsy samples. Ten primary NPC biopsy samples, pathologically validated, were obtained from the Department of Otolaryngology, National Taiwan University Hospital. Ten samples of nasopharyngeal tissues from patients with lymphohyperplasia (LH), containing nonmalignant epithelium and lymphocytes without pathological evidence of cancer cells, were also tested by Q-PCR.
| |
RESULTS |
|---|
|
|
|---|
Establishment of Zta expression cell clones.
It has been known
for a long time that the EBV lytic cycle occurs in vivo in epithelial
cells, and expression of the Zta protein has been documented in NPC and
oral hairy leukoplakia (OHL) (8, 30, 64). However, it
is difficult to obtain sufficient material to investigate the effect of
Zta in epithelial cells. To overcome this obstacle, three human
epithelial cell lines which express Zta have been established in
RHEK-1, NPC-TW01, and HONE-1. Zta protein expression may be detected by
Western blot analysis in transient transfectants and in stable clones
of RHEK-Z2, RHEK-Z3, and NPC-TW01-Z cells (Fig.
1A). The amount of Zta protein expressed in all transfectants was equivalent to or below that in P3HR-1 cells
which were activated in the lytic cycle (Fig. 1A). An
immunofluorescence assay was carried out to determine the percentage of
cells expressing the Zta protein and its location. As expected, most of
the Zta protein was located in the nuclei of the cells. Large
quantities of the protein were detected in transient transfectants but
only in a small percentage of the cells (Fig. 1B). Conversely, more than 90% of stable transfectants express the Zta protein but at a
lower level (data not shown).
|
Identification of a unique tyrosine kinase in Zta-expressing clones
using the kinase display assay.
Because of the importance of
tyrosine kinases in cellular control, we focused our investigation on
the identification of Zta-regulated tyrosine kinases. Taking advantage
of a two-step kinase display system, the tyrosine kinase profiles of
Zta-expressing and control cells were displayed following amplification
of tyrosine kinase transcripts using degenerate primers, which were
based on the conserved DVW and DFG motifs found in most tyrosine
kinases (27). The advantage of this newly developed assay is
that each tyrosine kinase may be recognized by its unique restriction
enzyme digestion pattern in the variable regions between the DVW
and DFG motifs (27). Analysis of the restriction
profiles revealed that the most prominent, differentially regulated
tyrosine kinase in the Zta-expressing clones is TKT (also known as
DDR2) (23). The unique TKT profile, which was apparent
in four different restriction enzyme profiles (Bsp1286I,
BstNI, HpaII, and AciI), was seen only in Zta-expressing stable clones and not in vector controls (Fig. 2). Similar findings were observed
following transient transfection (data not shown). The
differences in the HpaII and AciI digestion profiles for NPC-TW01-Z are not as clear as those for RHEK-Z2 and
RHEK-Z3. This could be due to the comigration of bands derived from
other kinases, which may be present in the NPC-TW01 cell line but not
in the RHEK-1 cell line.
|
Verification of the induction of TKT expression by Zta.
To
confirm the induction of TKT transcripts in Zta-expressing cells,
TKT-specific primers located in the extracellular region were used for
RT-PCR. The upregulation of TKT transcripts was demonstrated clearly in
Zta-expressing transient transfectants and in three independent stable
clones, NPC-TW01-Z, RHEK-Z2, and RHEK-Z3, but was not apparent in
control cells (Fig. 3A). Similar results
were obtained with HONE-1 cells with an inducible Zta expression system
(Fig. 3B). In the presence of doxycycline, the expression of TKT
increased significantly followed by an increase in Zta expression;
however, trace levels of TKT transcripts could be detected in the
absence of doxycycline due to the low level of Zta leakage. Certainly,
there were no detectable TKT transcripts in the pUHD10.3 vector
control, even in the presence of doxycycline (Fig. 3B). These results
indicated that Zta could upregulate TKT at the transcriptional
level, independent of cell type (NPC-TW01, RHEK-1, or HONE-1 cells) and
transfection system (transient transfection, constitutive expression
stable clones, or tet-on system).
|
Detection of TKT protein expression and status in Zta
transfectants.
We investigated TKT expression at a translational
level by Western blot analysis. As shown in Fig.
4A, a protein of approximately 125 kDa
was detected by a TKT-specific antibody in Zta transfectants but not in
control cells; the molecular mass is consistent with a previous report
(61). In this experiment, the pRc/CMV-TKT plasmid, carrying
the entire TKT open reading frame, was used as a positive control.
|
Investigation of the Zta domain required for TKT induction.
Structurally, Zta is a leucine zipper, DNA-binding protein containing a
DNA-binding domain, a transactivation domain, and a dimerization domain
(53). We wished to determine which domains of the Zta
protein are required for TKT induction. Various plasmids containing Zta
sequences with deletions in the transactivation or dimerization domains
were transfected into NPC-TW01 cells (13) and the levels of
TKT expression were estimated using Q-PCR. It may be seen that amino
acids 52 to 78 in the transactivation domain (Fig.
5A) and the dimerization domain of the
Zta protein (Fig. 5B) were both crucial for TKT induction. In this
experiment, the input mass of RNA was standardized by GAPDH RNA levels
and the data are presented after standardizing the Zta expression
levels for transfection efficiency.
|
Correlation of Zta and TKT expression in NPC biopsy specimens.
The possibility that trace amounts of Zta protein are sufficient to
induce TKT expression (Fig. 3 and 4) led us to question whether Zta
induces TKT expression in vivo. Q-PCR was carried out to determine the
levels of expression of Zta and TKT in NPC biopsy specimens (Fig.
6A). There was a significant correlation between the levels of expression of Zta and TKT. As controls, samples
from 10 patients with LH (normal nasopharyngeal tissues containing
nonmalignant squamous epithelium and lymphocytes) were tested for Zta
and TKT expression. TKT transcripts were detectable only with high
levels of Zta transcription, with one exception (Fig. 6B). In addition,
normal epithelial cells isolated from the nasal cavity were chosen to
examine the expression of Zta and TKT. In the three cases tested, Zta
transcripts were barely detected in the RT-PCR assay and no or only
trace amounts of TKT transcripts were demonstrated in the control cells
(data not shown). Moreover, through combination of NPC and LH data, the
correlation coefficient is 0.8 and the P value calculated by
the F test is <0.001. Simultaneously, the correlation between latent
membrane protein 1 (LMP-1), another EBV protein, and TKT was also
investigated in the NPC biopsy specimens. However, we did not find any
correlation between LMP-1 and TKT (unpublished data). Thus, it seemed
that Zta may upregulate TKT expression in vivo, as well as in cell culture.
|
| |
DISCUSSION |
|---|
|
|
|---|
Several reports suggest that EBV lytic transcripts, proteins, or
antibodies to them may be detected in EBV-related diseases (25), but their contribution to carcinogenesis remains
obscure. For example, Zta transcripts may be detected in NPC and OHL
biopsy specimens and high titers of antibodies to Zta may be detected in individuals with NPC or other EBV-related diseases but not in
healthy EBV carriers (8, 21, 25, 30, 57, 64). To date, many
reports have documented that Zta is the control switch in the EBV lytic
cycle and is responsible for the initiation of the lytic cascade
(25, 53). Moreover, Zta affects or cooperates with not only
EBV-encoded proteins but also many important cellular targets such as
c-Fos, TGF-
, p21, c-Jun, NF-
B, p53, c-Myb, the retinoic acid
receptor, and p300/CBP through a variety of mechanisms of action
(1, 5, 6, 11, 14, 17, 24, 47, 52, 53, 65, 66).
In this study, we adapted the newly developed tyrosine kinase display
system, which specifically displays transcripts of most of the known
tyrosine kinase genes (27), to explore the effects of Zta on
cellular signaling. Using kinase display, we found that TKT-specific
transcripts were induced in Zta-expressing cells but not in vector
control cells (Fig. 2). This finding was confirmed by RT-PCR and
Northern and Western blot analysis (Fig. 3 and 4A). Furthermore, the
importance of TKT in Zta-expressing cells was suggested by the
tyrosine-phosphorylated status of the TKT protein and by the
upregulation of TKT downstream effector MMP-1 (Fig. 4B and C). These
data imply that TKT may initiate a signaling cascade. Interestingly,
and consistent with the data from cultured cells, the levels of Zta and
TKT transcripts in NPC and LH biopsy specimens correlated closely with
each other (correlation coefficient is
0.8; P < 0.001) (Fig. 6). To our knowledge, this is the first evidence that
Zta may influence the expression of cellular genes both in vitro and in
vivo. Moreover, the requirement for the transactivation and
dimerization domains of the Zta protein in upregulating TKT in
transfected cells (Fig. 5) favors the direct involvement of Zta.
TKT is a receptor tyrosine kinase that comprises an extracellular
domain with discoidin I homology, an extended single-stretch transmembrane domain, and an intracellular catalytic tyrosine kinase
domain (23). Typically, proteins containing discoidin I-homologous motifs play an important physiological role in cell-cell contact or adhesion (54). For example, neurexin, which has a discoidin I domain, is believed to participate in neuron-glial cell
adhesion (38). Del-1, which is expressed in endothelial cells, is the ligand for intergrin
5
3
receptor. This ligand-receptor interaction promotes the adhesion of
endothelial cells (19). However, the physiological function
of TKT is not known. Recently, several studies of the expression
pattern, ligands, and downstream signals of TKT have provided clues to
its biological functions.
Several collagens (I, II, III, and V) have been identified as ligands which activate TKT, leading to the upregulation of MMP-1 (51, 61). Biologically, these collagens are major components of the extracellular matrix (ECM), which separates epithelial and stromal cells (32). Under certain physiological conditions, such as wound healing or tissue development, the epithelial or surrounding stromal cells secrete proteases which degrade the ECM, leading to cell migration and tissue reconstruction (32). MMPs play a major role in this process, and MMP-1 is essential for wound healing (41).
As well as facilitating tissue reconstruction and cell migration through the collagen matrix during wound healing (41, 42), MMP-1 is overexpressed in head and neck tumors, Ras-transformed papilloma-derived cells, and lung cancer and is associated with a poor prognosis for colon tumors (4, 31, 34, 35, 43). Moreover, MMP-1 expression leads to epidermal hyperplasia and increased susceptibility to tumor formation in a transgenic mouse model (9). MMP-1 may play an important role in carcinogenesis by destabilizing the ECM and basal lamina. This could allow tumor cells to grow or to metastasize by gaining access to the vascular and lymphatic systems (32).
Interestingly, TKT transcripts were suggested to be expressed in a collagen I-dependent hepatic wound-healing model in the rat (3). In this model, collagen is needed for cell cycle progression and TKT may be involved in the wound-healing process (3). Like its downstream effector, MMP-1, TKT is believed to be expressed in tumors such as prostate carcinoma, pediatric brain tumors, primary colon adenocarcinoma, and SK-Mel-2 (simian virus 40-transformed cell lines) (2, 46, 62). All these studies suggest that TKT may be involved in tissue-remodeling processes, such as wound healing or carcinogenesis (2, 3, 46, 60, 62). Collagen, TKT, and MMP-1 may be involved in regulating the microenvironment of the collagen barrier and may affect the migration of epithelial cells during wound healing or malignancy (60).
A model for NPC development may be proposed on the basis of Zta expression leading to TKT activation and MMP-1 upregulation. This newly synthesized MMP-1 can break down the ECM and promote cancer cell proliferation or migration. Furthermore, MMP-1 may cooperate with MMP9, which can be upregulated by another EBV protein, LMP-1, to facilitate tumor progression (63). These factors may explain the extraordinarily high incidence of metastases in NPC and are consistent with the finding of an in vivo increase in the level of more than one type of MMP in carcinogenesis (12, 20).
| |
ACKNOWLEDGMENTS |
|---|
We thank Hua-Chien Chen (Biotechnology and Pharmaceutical Research Division, National Health Research Institutes, Taipei, Taiwan) for technical assistance in the kinase display assay, and we thank Dan Robinson and Hsing-Jien Kung, University of California, Davis, for providing pCR2-TKT plasmid and the information about kinase display profile. We also thank Tzung-Shiahn Sheen for providing NPC and LH biopsy samples. We are deeply indebted to Tim J. Harrison of the Royal Free and University College Medical School of University College London (London, United Kingdom) for valuable discussions and for critically reviewing the manuscript.
This work was supported by the National Science Council (grants NSC 89-2318-B-002-005-M51 and NSC 90-2318-B-002-003-M51).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Room 714, Number 1, Section 1, Jen-Ai Road, Taipei, Taiwan, Republic of China. Phone: 886-2-2312-3456, ext. 8298. Fax: 886-2-2391-5180. E-mail: chtsai{at}ha.mc.ntu.edu.tw.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Adamson, A. L., and S. Kenney.
1999.
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.
J. Virol.
73:6551-6558 |
| 2. | Alves, F., W. Vogel, K. Mossie, B. Millaüer, H. Höfler, and A. Ullrich. 1995. Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene 10:609-618[Medline]. |
| 3. | Ankoma-Sey, V., M. Matli, K. B. Chang, A. Lalazar, D. B. Donner, L. Wong, R. S. Warren, and S. L. Friedman. 1998. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 17:115-121[CrossRef][Medline]. |
| 4. | Bolon, I., V. Gouyer, M. Devouassoux, B. Vandenbunder, N. Wernert, D. Moro, C. Brambilla, and E. Brambilla. 1995. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am. J. Pathol. 147:1298-1310[Abstract]. |
| 5. |
Cayrol, C., and E. K. Flemington.
1995.
Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor igh3 (TGF- igh3) and TGF- 1.
J. Virol.
69:4206-4212[Abstract].
|
| 6. | Cayrol, C., and E. K. Flemington. 1996. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J. 15:2748-2759[Medline]. |
| 7. |
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752 |
| 8. | Cochet, C., D. Martel-Renoir, V. Grunewald, J. Bosq, G. Cochet, G. Schwaab, J. F. Bernaudin, and I. Joab. 1993. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197:358-365[CrossRef][Medline]. |
| 9. | D'Armiento, J., T. DiColandrea, S. S. Dalal, Y. Okada, M.-T. Huang, A. H. Conney, and K. Chada. 1995. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol. Cell. Biol. 15:5732-5739[Abstract]. |
| 10. |
Doolittle, R. F.,
M. W. Hunkapiller,
L. E. Hood,
S. G. Devare,
K. C. Robbins,
S. A. Aaronson, and H. N. Antoniades.
1983.
Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor.
Science
221:275-277 |
| 11. |
Dreyfus, D. H.,
M. Nagasawa,
J. C. Pratt,
C. A. Kelleher, and E. W. Gelfand.
1999.
Inactivation of NF-kappaB by EBV BZLF-1-encoded ZEBRA protein in human T Cells.
J. Immunol.
163:6261-6268 |
| 12. |
Edwards, D. R., and G. Murphy.
1998.
Cancer. Proteases invasion and more.
Nature
394:527-528[CrossRef][Medline].
|
| 13. |
Flemington, E. K.,
A. M. Borras,
J. P. Lytle, and S. H. Speck.
1992.
Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain.
J. Virol.
66:922-929 |
| 14. |
Flemington, E. K., and S. H. Speck.
1990.
Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos.
J. Virol.
64:4549-4552 |
| 15. |
Glaser, R.,
H. Y. Zhang,
K. Yao,
H. C. Zhu,
F. X. Wang,
G. Y. Li,
D. S. Wen, and Y. P. Li.
1989.
Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas.
Proc. Natl. Acad. Sci. USA
86:9524-9528 |
| 16. |
Gossen, M.,
S. Freundieb,
G. Bender,
G. Muiller,
W. Hillen, and H. Bujard.
1995.
Transcriptional activation by tetracyclines in mammalian cells.
Science
268:1766-1769 |
| 17. |
Gutsch, D. E.,
E. A. Holley-Guthrie,
Q. Zhang,
B. Stein,
M. A. Blanar,
A. S. Baldwin, and S. C. Kenney.
1994.
The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B.
Mol. Cell. Biol.
14:1939-1948 |
| 18. |
Heid, C.
1996.
Real time quantitative PCR.
Genome Res.
6:986-994 |
| 19. |
Hidai, C.,
T. Zupancic,
K. Penta,
A. Mikhail,
M. Kawana,
E. E. Quertermous,
Y. Aoka,
M. Fukagawa,
Y. Matsui,
D. Platika,
R. Auerbach,
B. L. M. Hogan,
R. Snodgrass, and T. Quertermous.
1998.
Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alpha5beta3 integrin receptor.
Genes Dev.
12:21-33 |
| 20. | Hsu, M. M. 1993. Clinical and pathological characteristics of nasopharygeal carcinoma. Asian J. Surg. 16:280-288. |
| 21. | Joab, I., J. C. Nicolas, G. Schwaab, G. de-The, B. Clausse, M. Perricaudet, and Y. Zeng. 1991. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int. J. Cancer 48:647-649[Medline]. |
| 22. | Johnsson, A., C. Betsholtz, C. H. Heldin, and B. Westermark. 1986. The phenotypic characteristics of simian sarcoma virus-transformed human fibroblasts suggest that the v-sis gene product acts solely as a PDGF receptor agonist in cell transformation. EMBO J. 5:1535-1541[Medline]. |
| 23. | Karn, T., U. Holtrich, A. Brauninger, B. Bohme, G. Wolf, H. Rubsamen-Waigmann, and K. Strebhardt. 1993. Structure, expression and chromosomal mapping of TKT from man and mouse: a new subclass of receptor tyrosine kinases with a factor VIII-like domain. Oncogene 8:3433-3440[Medline]. |
| 24. |
Kenney, S. C.,
E. Holley-Guthrie,
E. B. Quinlivan,
D. Gutsch,
Q. Zhang,
T. Bender,
J. F. Giot, and A. Sergeant.
1992.
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.
Mol. Cell. Biol.
12:136-146 |
| 25. | Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2396. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa. |
| 26. | Kolibaba, K. S., and B. J. Druker. 1997. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333:F217-F248[Medline]. |
| 27. | Kung, H. J., H. C. Chen, and D. Robinson. 1998. Molecular profiling of tyrosine kinases in normal and cancer cells. J. Biomed. Sci. 5:74-78[CrossRef][Medline]. |
| 28. | Lai, C., and G. Lemke. 1994. Structure and expression of the Tyro 10 receptor tyrosine kinase. Oncogene 9:877-883[Medline]. |
| 29. | Lin, C. T., C. I. Wong, W. Y. Chan, K. W. Tzung, J. K. C. Ho, M. M. Hsu, and S. M. Chuang. 1990. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab. Investig. 62:713-724[Medline]. |
| 30. |
Martel-Renoir, D.,
V. Grunewald,
R. Touitou,
G. Schwaab, and I. Joab.
1995.
Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies.
J. Gen. Virol.
76:1401-1408 |
| 31. | Matrisian, L. M., S. McDonnell, D. B. Miller, M. Navre, E. A. Seftor, and M. J. C. Hendrix. 1991. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am. J. Med. Sci. 302:157-162[Medline]. |
| 32. |
Mignatti, P., and D. B. Rifkin.
1993.
Biology and biochemistry of proteinases in tumor invasion.
Physiol. Rev.
73:161-195 |
| 33. | Mosier, D. E. 1999. Epstein-Barr virus and lymphoproliferative disease. Curr. Opin. Hematol. 6:25-29[CrossRef][Medline]. |
| 34. | Muller, D., R. Breathnach, A. Engelmann, R. Millon, G. Bronner, H. Flesch, P. Dumont, M. Eber, and J. Abecassis. 1991. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int. J. Cancer 48:550-556[Medline]. |
| 35. | Murray, G. I., M. E. Duncan, P. O'Neil, W. T. Melvin, and J. E. Fothergill. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2:461-462[CrossRef][Medline]. |
| 36. | Niedobitek, G., A. Agathanggelou, and J. M. Nicholls. 1996. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin. Cancer Biol. 7:165-174[CrossRef][Medline]. |
| 37. |
Nishikawa, J.,
S. Imai,
T. Oda,
T. Kojima,
K. Okita, and K. Takada.
1999.
Epstein-Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression.
J. Virol.
73:1286-1292 |
| 38. | Peles, E., M. Nativ, M. Lustig, M. Grumet, J. Schilling, R. Martinez, G. D. Plowman, and J. Schlessinger. 1997. Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J. 16:978-988[CrossRef][Medline]. |
| 39. |
Petti, L., and D. DiMaio.
1992.
Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells.
Proc. Natl. Acad. Sci. USA
89:6736-6740 |
| 40. | Petti, L., L. A. Nilson, and D. DiMaio. 1991. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J. 10:845-855[Medline]. |
| 41. | Pilcher, B. K., B. D. Sudbeck, J. A. Dumin, H. G. Welgus, and W. C. Parks. 1998. Collagenase-1 and collagen in epidermal repair. Arch. Dermatol. Res. 290:S37-S46. |
| 42. |
Pilcher, B. K.,
J. A. Dumin,
B. D. Sudbeck,
S. M. Krane,
H. G. Welgus, and W. C. Parks.
1997.
The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix.
J. Cell Biol.
137:1445-1457 |
| 43. | Polette, M., C. Clavel, D. Muller, J. Abecassis, I. Binninger, and P. Birembaut. 1991. Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 11:76-83[Medline]. |
| 44. | Rak, J., J. Filmus, G. Finkenzeller, S. Grugel, D. Marmé, and R. S. Kerbel. 1995. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14:263-277[CrossRef][Medline]. |
| 45. | Rhim, J. S., G. Jay, P. Arnstein, F. M. Price, K. K. Sanford, and S. A. Aaronson. 1989. Neoplastic transformation of human epithelial cells in vitro. Anticancer Res. 9:1345-1365[Medline]. |
| 46. |
Robinson, D.,
F. He,
T. Pretlow, and H. J. Kung.
1996.
A tyrosine kinase profile of prostate carcinoma.
Proc. Natl. Acad. Sci. USA
93:5958-5962 |
| 47. |
Sato, H.,
H. Takeshita,
M. Furukawa, and M. Seiki.
1992.
Epstein-Barr virus BZLF1 transactivator is a negative regulator of Jun.
J. Virol.
66:4732-4736 |
| 48. | Schenk, P. W., and B. E. Snaar-Jagalska. 1999. Signal perception and transduction: the role of protein kinases. Biochim. Biophys. Acta 1449:1-24[Medline]. |
| 49. | Sheu, L. F., A. Chen, C. L. Meng, K. C. Ho, W. H. Lee, F. J. Leu, and C. F. Chao. 1996. Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo. J. Pathol. 180:243-248[CrossRef][Medline]. |
| 50. |
Shope, T.,
D. Dechairo, and G. Miller.
1973.
Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.
Proc. Natl. Acad. Sci. USA
70:2487-2491 |
| 51. | Shrivastava, A., C. Radziejewski, E. Campbell, L. Kovac, M. McGlynn, T. E. Ryan, S. Davis, M. P. Goldfarb, D. J. Glass, G. Lemke, and G. D. Yancopoulos. 1997. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol. Cell 1:25-34[CrossRef][Medline]. |
| 52. |
Sinclair, A. J.,
M. Brimmell, and P. J. Farrell.
1992.
Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression.
J. Virol.
66:70-77 |
| 53. | Speck, S. H., T. Chatila, and E. Flemington. 1997. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 5:399-405[CrossRef][Medline]. |
| 54. | Springer, W. R., D. N. Cooper, and S. H. Barondes. 1984. Discoidin I is implicated in cell-substratum attachment and ordered cell migration of Dictyostelium discoideum and resembles fibronectin. Cell 39:557-564[CrossRef][Medline]. |
| 55. | Sun, Y., G. Hegamyer, and N. H. Colburn. 1993. Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene 8:791-795[Medline]. |
| 56. |
Sun, Y.,
G. Hegamyer,
Y. J. Cheng,
A. Hildesheim,
J. Y. Chen,
I. H. Chen,
Y. Cao,
K. T. Yao, and N. H. Colburn.
1992.
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.
Proc. Natl. Acad. Sci. USA
89:6516-6520 |
| 57. |
Tedeschi, R.,
Y. T. Foong,
H. M. Cheng,
P. dePaoli,
T. Lehtinen,
T. Elfborg, and J. Dillner.
1995.
The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes.
J. Gen. Virol.
76:1393-1400 |
| 58. | Tokunaga, M., C. E. Land, Y. Uemura, T. Tokudome, S. Tanaka, and E. Sato. 1993. Epstein-Barr virus in gastric carcinoma. Am. J. Pathol. 143:1250-1254[Abstract]. |
| 59. | Tsai, C. H., M. T. Liu, M. R. Chen, J. Lu, H. L. Yang, J. Y. Chen, and C. S. Yang. 1997. Characterization of monoclonal antibodies to the Zta and DNase proteins of Epstein-Barr virus. J. Biomed. Sci. 4:69-77[CrossRef][Medline]. |
| 60. |
Vogel, W.
1999.
Discoidin domain receptors: structural relations and functional implications.
FASEB J.
13:S77-S82 |
| 61. | Vogel, W., G. D. Gish, F. Alves, and T. Pawson. 1997. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1:13-23[CrossRef][Medline]. |
| 62. | Weiner, H. L., M. Rothman, D. C. Miller, and E. B. Ziff. 1996. Pediatric brain tumors express multiple receptor tyrosine kinases including novel cell adhesion kinases. Pediatr. Neurosurg. 25:64-72[Medline]. |
| 63. |
Yoshizaki, T.,
H. Sato,
M. Furukawa, and J. S. Pagano.
1998.
The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1.
Proc. Natl. Acad. Sci. USA
95:3621-3626 |
| 64. |
Young, L. S.,
R. Lau,
M. Rowe,
G. Niedobitek,
G. Packham,
F. Shanahan,
D. T. Rowe,
D. Greenspan,
J. S. Greenspan,
A. B. Rickinson, and P. J. Farrell.
1991.
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.
J. Virol.
65:2868-2874 |
| 65. |
Zerby, D.,
C. J. Chen,
E. Poon,
D. Lee,
R. Shiekhattar, and P. M. Lieberman.
1999.
The amino-terminal C/H1 domain of CREB binding protein mediates Zta transcriptional activation of latent Epstein-Barr virus.
Mol. Cell. Biol.
19:1617-1626 |
| 66. |
Zhang, Q.,
D. Gutsch, and S. C. Kenney.
1994.
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.
Mol. Cell. Biol.
14:1929-1938 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»